美迈德生物

最新新闻

• 评级变动
  Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating, Announces Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/4/17
• Lake Street Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  A Quick Look at Today's Ratings for MiMedx(MDXG.US), With a Forecast Between $5 to $8
  \u5e02\u573a\u8d44\u8baf · 2026/5/1
• 评级变动
  Lake Street Maintains MiMedx(MDXG.US) With Buy Rating, Cuts Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/1/20
• 评级变动
  Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2025/12/23
• 评级变动
  Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Cuts Target Price to $6
  \u5e02\u573a\u8d44\u8baf · 2026/4/17
• 评级变动
  Lake Street Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating, Announces Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2025/12/26
• 评级变动
  Citizens JMP Maintains MiMedx(MDXG.US) With Buy Rating, Cuts Target Price to $7
  \u5e02\u573a\u8d44\u8baf · 2026/4/18
• 评级变动
  Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Cuts Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/1/20
• Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating, Announces Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Citizens JMP Initiates MiMedx(MDXG.US) With Buy Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/2/23
• 评级变动
  Mizuho Securities Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/4/13
• 评级变动
  Citizens JMP Maintains MiMedx(MDXG.US) With Buy Rating, Cuts Target Price to $6
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 评级变动
  Northland Securities Maintains MiMedx(MDXG.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (AGL), MiMedx Group (MDXG) and Park Dental Partners, Inc. (PARK)
  TipRanks · 2026/2/27
• Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Lake Street Maintains MiMedx(MDXG.US) With Buy Rating, Cuts Target Price to $5
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating, Cuts Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/1/23
• Lake Street Maintains MiMedx(MDXG.US) With Buy Rating, Raises Target Price to $7
  \u5e02\u573a\u8d44\u8baf · 2026/7/30

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。